Disease · MONDO_0019297

lymphedema

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lymphedema. Diseases, record MONDO_0019297. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019297

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lymphedema; Open Targets
Open Targets ID: MONDO_0019297; Open Targets
Other names: Lymphatic obstruction, Lymphoedema, Onset of lymphedema around puberty, Swelling caused by excess lymph fluid under skin, lymphatic edema (morphologic abnormality), lymphatic oedema, lymphatic oedema (morphologic abnormality); Open Targets
Disease Ontology: DOID:4977; Disease Ontology
MeSH: D008209; MeSH
NCI Thesaurus: C3207; NCI Thesaurus
Orphanet: ORPHA:79383; Orphanet
Highest stage of its drugs: Approval, for 1 of its 21 drugs, from DailyMed; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ZINC OXIDE	CHEMBL3988900	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
FIBRIN	CHEMBL2108390		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
TACROLIMUS ANHYDROUS	CHEMBL269732	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
KETOPROFEN	CHEMBL571	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
OXYGEN	CHEMBL1234886	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PENTOXIFYLLINE	CHEMBL628	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
VITAMIN E	CHEMBL3989727		Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
ACEBILUSTAT	CHEMBL4297604	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MARITIME PINE	CHEMBL2109208		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets51

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2/3	https://conductscience.org/library/genes/2280	Drugs and targets
ADORA2A	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/136	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	1	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
CYP19A1	Aromatase	1	Cytochrome P450 19A1 inhibitor	Unknown	https://conductscience.org/library/genes/1588	Drugs and targets
FGFR1	Fibroblast growth factor receptor 1	1	Fibroblast growth factor receptor 1 inhibitor	Phase 2	https://conductscience.org/library/genes/2260	Drugs and targets
FGFR3	Fibroblast growth factor receptor 3	1	Fibroblast growth factor receptor 3 inhibitor	Phase 2	https://conductscience.org/library/genes/2261	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets

1 to 10 of 51

See all 51 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02700529	Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)	Phase 2	54	2023-01-18	Lymphedema	UBENIMEX	Its record names the disease	ClinicalTrials.gov
NCT00827372	A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer	Phase 2	10	2014-10-16	Lymphedema	PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT01928030	Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer	Phase 1/2	3	2017-02-07	Lymphedema, Malignant Neoplasm	HYALURONIDASE	Its record names the disease	ClinicalTrials.gov
NCT02595996	Propranolol Dose Escalation in Lymphedema in Patients	Phase 2	1	2021-10-22	Primary Lymphedema	PROPRANOLOL	Its record names the disease	ClinicalTrials.gov
NCT06912763	Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)	Phase 2	250		Fibrosis Syndrome, Lymphedema, Head &Amp; Neck Cancer, Fibrosis	KETOPROFEN, PENTOXIFYLLINE, PRAVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT02929121	A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India	Phase 3	235		Lymphedema, Lymphatic Filariasis, Filariasis	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT02927496	A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali	Phase 3	220		Lymphedema, Lymphatic Filariasis, Filariasis	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT02929134	A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka	Phase 3	219		Lymphedema, Lymphatic Filariasis, Filariasis	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT04792840	Skeletal Events of Hormonal Treatment and Radiotherapy in Patient With Breast Cacer		100		Breast Cancer	LETROZOLE	Its record names the disease	ClinicalTrials.gov
NCT06306274	Topical Tacrolimus for Breast Cancer-related Lymphedema	Phase 2/3	80		Lymphedema	TACROLIMUS ANHYDROUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ubenimex vs Placebo: deaths from any cause	0 of 27	0 of 27	54	NCT02700529	Trial comparisons
Ubenimex vs Placebo: serious adverse events	1 of 27	1 of 27	54	NCT02700529	Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31815082	RESULT	1	PubMed
30333315	RESULT	1	PubMed
22610930	RESULT	3	PubMed
20027220	RESULT	1	PubMed
15542159	RESULT	1	PubMed
11873261	RESULT	3	PubMed
10656038	RESULT	2	PubMed
40200322	DERIVED	1	PubMed
36762782	DERIVED	1	PubMed
32228663	DERIVED	3	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019297

GET https://conductscience.org/api/diseases/v1/MONDO_0019297/drugs?page=2

API reference For AI assistants